📣 VC round data is live. Check it out!

Rise Valuation Multiples

Discover revenue and EBITDA valuation multiples for Rise and similar public comparables like Pilulka Lekarny, Farmacosmo, SC Ropharma, Wellgistics Health and more.

Rise Overview

About Rise

Rise Inc is engaged in real estate business. The operations of the company include development of real estate and rental of real estate. The company conduct business to develop hotels, condominiums, residential properties, and commercial facilities.


Founded

1947

HQ

Japan

Employees

3

Sectors

Financials (FY)

Revenue: $3M
EBITDA: $664K

EV

$16M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Rise Financials

Rise reported last fiscal year revenue of $3M and EBITDA of $664K.

In the same fiscal year, Rise generated $2M in gross profit, $664K in EBITDA, and $63K in net income.


Rise P&L

In the most recent fiscal year, Rise reported revenue of $3M and EBITDA of $664K.

Rise is profitable as of last fiscal year, with gross margin of 77%, EBITDA margin of 25%, and net margin of 2%.

See analyst estimates for Rise
Last FY202320242025202620272028
Revenue$3M$2M$2M$2M
Gross Profit$2M$2M$2M$2M
Gross Margin77%84%84%84%
EBITDA$664K$547K$613K$664K
EBITDA Margin25%25%26%27%
EBIT Margin9%3%8%9%
Net Profit$63K($14K)$26K$57K
Net Margin2%(1%)1%2%

Financial data powered by Morningstar, Inc.

Rise Stock Performance

Rise has current market cap of $18M, and enterprise value of $16M.


Rise's stock price is $0.19.

See more trading valuation data for Rise
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$16M$18M0.1%$0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Rise Valuation Multiples

Rise trades at 6.0x EV/Revenue multiple, and 24.0x EV/EBITDA.

See NTM and 2027E valuation multiples for Rise

Rise Financial Valuation Multiples

As of May 10, 2026, Rise has market cap of $18M and EV of $16M.

Rise has a P/E ratio of 293.5x.

Last FY202320242025202620272028
EV/Revenue6.0x7.2x6.7x6.5x
EV/EBITDA24.0x29.1x26.0x24.0x
EV/EBIT67.2x207.6x83.0x71.2x
EV/Gross Profit7.8x8.6x7.9x7.8x
P/En/mn/mn/mn/m
EV/FCF44.5x(203.4x)67.3x44.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Rise Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Rise Margins & Growth Rates

In the most recent fiscal year, Rise reported gross margin of 77%, EBITDA margin of 25%, and net margin of 2%.

See estimated margins and future growth rates for Rise

Rise Margins

Last FY20242025202720282029
Gross Margin77%84%84%
EBITDA Margin25%26%27%
EBIT Margin9%8%9%
Net Margin2%1%2%
FCF Margin13%10%15%

Rise Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth8%2%
Gross Profit Growth9%2%
EBITDA Growth12%8%
EBIT Growth150%17%
Net Profit Growth(278%)125%
FCF Growth(402%)51%

Data powered by FactSet, Inc. and Morningstar, Inc.

Rise Operational KPIs

Rise's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.6M for the same period.

Access forward-looking KPIs for Rise
Last FY202320242025202620272028
Revenue per Employee$0.9M
Opex per Employee$0.6M
Opex to Revenue68%80%76%75%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Rise Competitors

Rise competitors include Pilulka Lekarny, Farmacosmo, SC Ropharma, Wellgistics Health, Talea Group, PetMeds, d1000, BlueMTec, MARX Biotech and Green Cross Health.

Most Rise public comparables operate across Pharmacies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Pilulka Lekarny0.3x(8.2x)
Farmacosmo0.3x25.7x
SC Ropharma0.2x4.4x
Wellgistics Health1.5x(0.4x)
Talea Group0.6x24.4x
PetMeds0.1x0.1x3.4x(0.6x)
d10000.3x3.8x
BlueMTec0.7x105.5x

This data is available for Pro users. Sign up to see all Rise competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Rise

When was Rise founded?Rise was founded in 1947.
Where is Rise headquartered?Rise is headquartered in Japan.
How many employees does Rise have?As of today, Rise has over 3 employees.
Is Rise publicly listed?Yes, Rise is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of Rise?Rise trades under 8836 ticker.
When did Rise go public?Rise went public in 1972.
Who are competitors of Rise?Rise main competitors include Pilulka Lekarny, Farmacosmo, SC Ropharma, Wellgistics Health, Talea Group, PetMeds, d1000, BlueMTec, MARX Biotech, Green Cross Health.
What is the current market cap of Rise?Rise's current market cap is $18M.
What is the current revenue of Rise?Rise's last fiscal year revenue is $3M.
What is the current EV/Revenue multiple of Rise?Current revenue multiple of Rise is 6.0x.
Is Rise profitable?No, Rise is not profitable.
How many companies Rise has acquired to date?Rise hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Rise has invested to date?Rise hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Rise

Lists including Rise

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial